Table 1.
Detailed Baseline Demographics, Risk Factors, Comorbidities, and Other Descriptors in all REPRIEVE Participants and Stratified by PCAT Density
| Demographics | n/N (%), Mean ± SD, or Median (25%–75%) | PCAT Density–HU Median (25%–75%) | P Value |
|---|---|---|---|
| Age, y | 50.8 ± 5.8 | … | |
| Age categories, y | .998 | ||
| 40–44 | 102 (14.0) | −88.8 (−95.9 to −80.3) | |
| 45–49 | 208 (28.6) | −88.8 (−95.9 to −80.3) | |
| 50–54 | 228 (31.4) | −88.6 (−94.2 to −82.4) | |
| 55–59 | 135 (18.6) | −89.1 (−94.6 to −82.0) | |
| ≥60 | 54 (7.4) | −88.5 (−94.6 to −79.8) | |
| Sex | .026 | ||
| Female | 119 (16.4) | −91.0 (−97.2 to −83.6) | |
| Male | 608 (83.6) | −88.2 (−94.6 to −80.9) | |
| Race | … | … | <.001 |
| White | 388 (53.4) | −89.5 (−95.7 to −82.7) | |
| Black or African American | 257 (35.4) | −86.4 (−92.8 to −78.6) | |
| Asian | 10 (1.4) | −89.8 (−91.5 to −85.0) | |
| Other | 72 (9.9) | −90.3 (−96.7 to −82.6) | |
| Ethnicity | .004 | ||
| Hispanic or Latino | 176 (24.2) | −90.7 (−96.0 to −84.8) | |
| Not Hispanic or Latino | 541 (74.4) | −87.8 (−94.6 to −80.4) | |
| Unknown | 10 (1.4) | −91.4 (−94.2 to −78.7) | |
| Behavioral risk factors | |||
| Smoking status | .003 | ||
| Current | 176 (24.2) | −86.7 (−92.8 to −78.4) | |
| Former | 227 (31.3) | −88.9 (−95.3 to −82.0) | |
| Never | 323 (44.5) | −89.8 (−95.9 to −81.2) | |
| Substance usea | <.001 | ||
| Current | 16 (2.2) | −80.2 (−86.3 to −75.7) | |
| Former | 357 (49.2) | −87.1 (−93.0 to −79.9) | |
| Never | 352 (48.6) | −91.2 (−97.0 to −83.5) | |
| Cardiovascular risk factors | |||
| Family history of premature disease | .529 | ||
| Yes | 164 (22.6) | −89.8 (−95.5 to −82.5) | |
| No | 540 (74.5) | −88.4 (−94.8 to −81.0) | |
| Unknown | 21 (2.9) | −88.2 (−95.3 to −80.5) | |
| Prior statin use | .586 | ||
| Yes | 57 (7.8) | −88.3 (−92.6 to −80.9) | |
| No | 670 (92.2) | −88.9 (−95.3 to −81.2) | |
| History of hypertension | .861 | ||
| Yes | 228 (31.4) | −88.0 (−95.3 to −81.6) | |
| No | 499 (68.6) | −88.9 (−94.8 to −81.1) | |
| Median ASCVD risk score, % | 4.5 (2.6–6.8) | … | |
| ASCVD risk categories, % | .613 | ||
| <2.5 | 168 (23.1) | −89.4 (−95.2 to −81.7) | |
| 2.5–4.9 | 238 (32.7) | −89.0 (−95.2 to −80.8) | |
| 5.0–7.4 | 177 (24.4) | −88.3 (−95.8 to −81.6) | |
| 7.5–9.9 | 98 (13.5) | −87.9 (−94.6 to −81.6) | |
| ≥10.0 | 46 (6.3) | −87.3 (−92.4 to −79.7) | |
| Metabolic risk factors and orthometric measures | |||
| BMI, kg/m2 | 27.3 ± 4.4 | … | |
| BMI categories, kg/m2 | .001 | ||
| <18.5 | 8 (1.1) | −79.0 (−99.1 to −74.1) | |
| 18.5–24.9 | 238 (32.7) | −86.6 (−92.3 to −79.0) | |
| 25–29.9 | 295 (40.6) | −90.0 (−95.8 to −82.0) | |
| 30–34.9 | 142 (19.5) | −90.1 (−95.7 to −84.0) | |
| ≥35 | 44 (6.1) | −89.3 (−95.8 to −83.2) | |
| Waist circumference, cm | 95.6 ± 11.9 | … | |
| Waist circumference categories | <.001 | ||
| High (male: ≥102 cm; female ≥88 cm) | 220 (31.9) | −90.9 (−95.5 to −84.2) | |
| Normal (male: <102 cm; female <88 cm) | 469 (68.1) | −87.7 (−94.3 to −79.9) | |
| HIV parameters | |||
| HIV RNA, copies/mL | .039 | ||
| <LLQ | 633 (88.2) | −89.2 (−95.3 to −81.6) | |
| LLQ, <400 | 70 (9.8) | −86.8 (−91.9 to −79.6) | |
| ≥400 | 15 (2.1) | −83.0 (−92.3 to −76.4) | |
| Total ART use | .742 | ||
| <5 y | 117 (16.1) | −89.6 (−95.2 to −79.7) | |
| 5–9.9 y | 190 (26.1) | −89.1 (−94.8 to −82.0) | |
| ≥10 y | 420 (57.8) | −88.3 (−94.9 to −81.2) | |
| ART regimen by class | .991 | ||
| NRTI + INSTI | 325 (44.7) | −88.6 (−95.3 to −81.6) | |
| NRTI + NNRTI | 190 (26.1) | −89.0 (−95.8 to −81.2) | |
| NRTI + PI | 121 (16.6) | −89.4 (−93.9 to −80.8) | |
| NRTI-sparing | 21 (2.9) | −86.6 (−95.1 to −82.8) | |
| Other NRTI-containing | 70 (9.6) | −88.3 (−94.2 to −80.8) | |
| Abacavir exposure | .834 | ||
| Yes | 246 (33.9) | −88.7 (−95.1 to −81.6) | |
| No | 479 (66.1) | −88.8 (−94.8 to −81.1) | |
| CD4, cells/mm3 | .779 | ||
| <350 | 110 (15.1) | −88.3 (−94.8 to −80.5) | |
| 350–499 | 145 (19.9) | −89.0 (−95.2 to −81.9) | |
| ≥500 | 472 (64.9) | −88.8 (−95.0 to −81.2) | |
| Nadir CD4, cells/mm3 | .186 | ||
| <50 | 157 (21.6) | −88.9 (−96.3 to −81.8) | |
| 50–199 | 212 (29.2) | −89.3 (−95.7 to −82.9) | |
| 200–349 | 196 (27.0) | −88.6 (−94.3 to −80.4) | |
| ≥350 | 140 (19.3) | −88.7 (−93.4 to −81.2) | |
| Unknown | 22 (3.0) | −84.5 (−90.9 to −75.3) |
aSubstance use among PWH was classified as current (2.2%) or former (49%) (IV drug [current: 0%, former: 11.2%], cocaine [current: 1.2%, former: 45.8%], or methamphetamine [current: 1.1%, former: 19.7%]. P values were obtained using a nonparametric Kruskal–Wallis test.
Abbreviations: ART, antiretroviral therapy; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; HIV, human immunodeficiency virus; HU, Hounsfield unit; INSTI, integrase strand transfer inhibitors; LLQ, lower level of quantification; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PCAT, pericoronary adipose tissue; PI, protease inhibitor; REPRIEVE, Randomized Trial to Prevent Vascular Events in HIV.